TRACT Therapeutics, Inc. has developed a novel approach for restoring immune balance in patients receiving a solid organ transplant or in patients suffering from an autoimmune disease. This therapeutic approach may potentially reduce the chance of organ rejection following a transplant or transfer a patient suffering from an autoimmune disease into a state of remission. The proprietary technology is based on a platform which can be utilized to treat solid organ transplant patients, as well as a number of autoimmune disorders such as Crohn’s Disease. For organ transplant, it shows great promise in preventing rejection of a donated organ, thereby, reducing the need for a second transplant. Over the next few years, TRACT’s TregCel™ personalized therapy could transform the medical approach in transplant medicine by dramatically reducing or eliminating the lifelong use of toxic anti-rejection drugs.
View Top Employees from TRACT Therapeutics, Inc.Website | https://www.tracttherapeutics.com/ |
Revenue | $6 million |
Employees | 5 (3 on RocketReach) |
Founded | 2013 |
Address | 1235 N Clybourn Ave # 338, Chicago, Illinois 60610, US |
Phone | (312) 815-8993 |
Fax | (312) 587-1088 |
Industry | Biotechnology, Biotechnology Research, Pharmaceuticals, Drug Discovery, Healthcare |
SIC | SIC Code 809 Companies, SIC Code 80 Companies |
NAICS | NAICS Code 6219 Companies, NAICS Code 621991 Companies, NAICS Code 62199 Companies, NAICS Code 62 Companies, NAICS Code 621 Companies |
Looking for a particular TRACT Therapeutics, Inc. employee's phone or email?
The TRACT Therapeutics, Inc. annual revenue was $6 million in 2024.
Cheryl Stratton is the Director Of Manufacturing of TRACT Therapeutics, Inc..
3 people are employed at TRACT Therapeutics, Inc..
TRACT Therapeutics, Inc. is based in Chicago, Illinois.
The NAICS codes for TRACT Therapeutics, Inc. are [6219, 621991, 62199, 62, 621].
The SIC codes for TRACT Therapeutics, Inc. are [809, 80].